

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31st December 2019
for
European Parkinson's Disease Association

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

**Contents of the Financial Statements
for the Year Ended 31st December 2019**

	Page
Report of the Trustees	1 to 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Statement of Financial Position	10
Statement of Cash Flows	11
Notes to the Statement of Cash Flows	12
Notes to the Financial Statements	13 to 19
Detailed Statement of Financial Activities	20 to 24

European Parkinson's Disease Association

Report of the Trustees for the Year Ended 31st December 2019

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2019. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2019**

OBJECTIVES AND ACTIVITIES

Overview of the EPDA

The European Parkinson's Disease Association (EPDA) is the only European Parkinson's umbrella organisation.

We have been championing and working with the global Parkinson's community for more than 25 years. It represents national Parkinson's associations in nearly 30 countries across Europe and advocates for the rights and needs of more than 1.2 million people with Parkinson's and their families. The EPDA is a non-political, non-religious and not-for-profit organisation.

As the leading voice for Parkinson's in Europe, its mission is to provide information and resources to all Parkinson's stakeholders, raise awareness of the disease's complexities and impact, and advocate for concrete policy change that benefits the Parkinson's community.

The EPDA's vision is to enable all people with Parkinson's to live a full life, while supporting the search for a cure.

Objectives

The EPDA has four overarching strategic objectives:

Goal 1

To advocate for people with Parkinson's and their families to get the right information at the right time throughout their Parkinson's journey.

Goal 2

To strive for healthcare systems where people with Parkinson's receive early and appropriate treatment and individualised care.

Goal 3

To raise awareness of the complexities of Parkinson's and the impact it has on people's quality of life.

Goal 4

To support the global Parkinson's community in the search for a cure.

We hope to achieve these objectives (and therefore our mission and vision) through the following strategies:

Engage

We engage and connect with the Parkinson's community across Europe and the globe to champion collaborations and partnerships, help develop solutions to unmet needs, and raise awareness of the impact of the disease with decision makers.

Visit www.epda.eu.com/get-involved

Inform

We provide up-to-date information, research and resources for Parkinson's stakeholders to educate, advise and share good practices.

Visit www.epda.eu.com/about-parkinsons

Unite

We represent national Parkinson's associations - that collectively have more than 120,000 members in nearly 30 countries across Europe - and advocate for the rights and needs of more than 1.2 million people with Parkinson's and their families.

Visit www.epda.eu.com/our-members

Advocate

We provide an authoritative voice on the impact of Parkinson's across Europe and advocate for policy change that benefits the European Parkinson's community.

Visit www.epda.eu.com/get-involved/advocacy

The main objective of the charity during the year was to continue working towards the goals listed above.

The main strategies for achieving the charity's objectives for the year was by engagement, facilitation and utilisation of the communication strategy, advocacy activities and project development.

European Parkinson's Disease Association

Report of the Trustees for the Year Ended 31st December 2019

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

2019 activities and successes

In 2019, we managed to substantially improve the EPDA's internal governance - reforming our Statutes, with the collaboration of our Members, and striving for increased transparency and democracy.

We engaged in multiple activities in support of our member organisations, doing what we do best: creating connections and facilitating partnerships.

We have been constantly increasing the EPDA's exposure - for example, through our participation in important scientific conferences - thereby raising the profile of the European Parkinson's community and ultimately on Parkinson's itself, and creating occasions for new and dynamic partnerships with the treatment industry.

We dedicated a substantial amount of time and resources to issues such as young-onset Parkinson's awareness, carers and supporting the search for a cure, as these issues are too often neglected at a European public health and decision-making level. And we plan to continue this trend in the years to come.

The EPDA Team would like to thank the Trustees for contributing with their knowledge, expertise and constant commitment to the positive results of the projects and activities detailed below.

In particular, in 2019 the EPDA achieved important successes in the areas listed below; each of the results highlighted are linked closely to our four key objectives (information and education; advocacy; awareness raising; research), and to the topics of governance and member organisations support

Governance

- Update of EPDA Statutes, with input and approval from our 30+ members
- Three new Board members since early 2019, bringing the total to 10
- Results:
 - o Increased transparency and democracy
 - o Smoother decision making process and internal functioning
 - o Improved expertise and representation in the Board
- See: <https://www.epda.eu.com/about-us/governance/>

Members

- Support in outreach, engagement, networking with EPDA member organisations
- Country visits and meetings with representatives of more than 10 member organisations
- Members' meeting 2019, including new sessions with experts on:
 - o Clinical trials - developed into 2020 Clinical Trials panel, with involvement of 10 MOs representatives
 - o Shortage of medicines - developing into 2020 guidelines
- Results:
 - o Improved two-way collaboration between EPDA and member organisations
 - o Development of partnered activities on topics that are fundamental for the European Parkinson's community
- See: <https://www.epda.eu.com/our-members/member-organisations/>

EPDA exposure

- Participation in high-profile international congresses
- Publications and advertisements in medical/scientific journals
- Results:
 - o Increased knowledge and awareness of Parkinson's in the medical/scientific community
 - o Increased knowledge and awareness of the EPDA work in the Parkinson's community
- See for example: https://www.epda.eu.com/get-involved/the-parkinsons-disease-composite-scale/#go_5

Young-onset Parkinson's awareness

- Started with an important event at the European Parliament (2018)
 - o A working group uniting YOPD people from all Europe - leading to a number of important activities in 2019:
 - o A 2019 international awareness campaign (#UNITED) was inspired by 2018 EPDA events (EU event and meeting) and the #UFP campaign
 - o A conference on women and Parkinson's (2019)
 - o A research on Parkinson's and working life (2019, results to be expected soon)
- Results: higher attention and awareness about YOPD at national and European level
- See: https://www.epda.eu.com/get-involved/advocacy/#go_4

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2019**

Carers awareness and support

- A comprehensive survey specifically on carers' challenges
- A successful workshop with 19 people from all over Europe (PwPs, carers, HCPs, experts): Belgium, Czech Republic, France, Ireland, Italy, the Netherlands, Portugal, Slovenia, Sweden, Spain
 - o A working group uniting YOPD people from all Europe - leading to a number of important activities in 2019:
 - o A 2019 international awareness campaign (#UNITED) was inspired by 2018 EPDA events (EU event and meeting) and the #UFP campaign
 - o A conference on women and Parkinson's (2019)
 - o A research on Parkinson's and working life (2019, results to be expected soon)
- Leading to promising results and significant exposure:
 - o Abstract presented for 2020 MDS Congress
 - o Scientific paper published in a peer-reviewed journal
 - o Report will become important advocacy tool
- Results:
 - o a stronger focus on carers from an advocacy and public health policy point of view
- See: <https://www.epda.eu.com/get-involved/caring-and-parkinson-s/>

Research

- TreatER project:
 - o long-time collaboration with Herantis Pharma and lead academic universities
 - o collaboration in a first-in-human clinical study with intracerebrally administered CDNF protein in people with Parkinson's using a neurosurgically implanted drug delivery system (DDS)
- European Parkinson's clinical trials advisory panel
- Collaboration with the Michael J Fox Foundation for Parkinson's Research
 - o Participation in clinical trials panel at Members' Meeting 2019
 - o Dissemination of information materials via EPDA website
- Sunovion CTH-302 trial
 - o Collaboration with treatment company and research institutions in 6 European countries
 - o Driving trial participation for the development of a new Parkinson's medicine
- Results:
 - o Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research
 - o More inclusive, effective and patient-friendly clinical trials
 - o Ultimately, the development of better treatment solutions for people with Parkinson's
- See: <https://www.epda.eu.com/get-involved/clinical-trials/>

Digital communications strategy

- Parkinson's Life:
 - o Podcast: six episodes in 2019 about important topics: parenting, caring, creativity, HCPs consultations
 - o Women and Parkinson's: an upbeat information/awareness campaign about how Parkinson's affects women specifically
- EPDA website
 - o Page views: 94% increase from December 2018 to December 2019
 - o Users: 65% increase from December 2018 to December 2019
 - o New sections:
- Clinical trials engagement
- Resources for healthcare professionals
- Social media:
 - o Facebook:
 - 44% increase in page views over the year
 - 20% increase in engagement over the year
 - o Twitter:
 - 43% increase in impressions over the year
 - 182% increase in retweets over the year
 - o Information & Education posts: 65% increase in reach and 70% increase in engagement over the year

Pharmaceutical Companies:

Abbott
AbbVie Biopharmaceuticals Sarl
Acorda Therapeutics
Air Liquide Healthcare
BIAL
Biogen

European Parkinson's Disease Association

Report of the Trustees for the Year Ended 31st December 2019

Boston Scientific International SA
Britannia Pharmaceuticals Ltd
Ever Neuro Pharma GmbH
Herantis Pharma Plc.
Lundbeck
Medtronic International Trading
UCB Biopharma SPR
Zambon SPA

Other funders:

Grayling
PD Warrior
Optim European Research
Oxford Health Policy Forum

Administration Board Members

The EPDA is administered by a Board of between five and ten members who are elected at the Members general assembly meeting for a term of three years. They may be re-elected at the end of this term for another three years.

Selection committee

In order to select potential EPDA Board nominees, the existing Board must appoint a selection committee that includes:

- one elected Board member
- one present-elected Board member if NOT standing for re-election (if all Board members are standing for re-election, the Board will select an alternative representative)
- one other chosen by the existing Board, normally the Executive Director
- a member organisation representative, who may or may not have Parkinson's.

The committee will search for and select nominations during the year immediately following the election of the present Board. It will then provide their written recommendation to the Board along with an evaluation of their discussions/communications with interested nominees.

The existing board

It is the existing Board's responsibility to:

- confirm that the EPDA budget can support the full participation of the proposed number of Board members
- strive for the widest possible geographic representation by its Board members
- submit successful nominations to the General Assembly for ratification by the delegates.

Nominees

Nominees must:

- meet personally with the elected board
- be enthusiastic and committed individuals who are familiar with - and have participated in - the EPDA's work during the previous three years
- understand the importance of the EPDA's aims and objectives, and commit to furthering these during their term of office for the benefit of the members and those individuals that they represent
- be either a person with Parkinson's, carer, patient organisation representative or healthcare professional
- must reflect the geographic spread of the EPDA
- have been actively involved in pursuing their respective organisation's initiatives, achievements and goals for a period of no less than five years
- confirm that the organisation they represent has fully paid its EPDA membership fees in the current year and for the last five years
- attend board meetings as an observer (in the year of the election).

General nominee requirements

Nominees must:

- have the ability to work and communicate in English
- demonstrate communication skills with a variety of people from different cultural backgrounds
- be a good team player and appreciate the importance of partnership and working together
- act as an ambassador and advocate for the EPDA

European Parkinson's Disease Association

Report of the Trustees for the Year Ended 31st December 2019

- have the willingness to accept and handle responsibility within the Board structure, if required
- show motivation and commitment
- have a sense of humour
- be available to travel widely and attend EPDA meetings in person, if required
- be willing to devote the time required to attend or participate (via conference call facilities) the EPDA meetings
- have flexible working arrangements and be able to fit in with weekend meetings and mid-week telephone conference calls

The charity's current policy concerning the payment of trade creditors is to:

- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that supplier are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance

Trade creditors of the company at the year-end were equivalent to 138 day's purchases, based on the average daily amount invoiced by suppliers during the year. Trade creditors at the year-end included one supplier account amounting to £95,116 (2018: £193,414) which had been issued late by the supplier. Excluding this invoice, the remaining trade creditors were equivalent to 54 day's purchases.

The day to day running of the Charity is carried out by the administration team under direct supervision of the management team i.e. Secretary General and Operations Director.

On appointment, new trustees are provided with a welcome pack which includes a brief history of the charity, copy administration board minutes, a copy of the last three years of annual report and accounts, a copy of the governing trust deed and a copy of the Charity Commission's guidance "The Essential Trustee: What You Need to Know" and "Public Benefit: running a charity".

All trustees give their time freely and no trustee remuneration for the services rendered as trustee was paid in the year. Ms M E Graham, a trustee of the charity, receives payments for consultancy work in connection with her role as Strategic Advisor.

Details of trustee expenses and related party transactions are disclosed in note 10 to the accounts.

FINANCIAL REVIEW

Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

CE004367 (England and Wales)

Registered Charity number

1163211

Registered office

Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

European Parkinson's Disease Association

Report of the Trustees
for the Year Ended 31st December 2019

Trustees

Mr K Onarheim
Ms M E Graham
Ms S Lindvall
Ms V Clark
Mr D J Lavender MBE
Ms V A Buxton
Ms P Gilmore

Independent Examiner

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Approved by order of the board of trustees on11 June 2020..... and signed on its behalf by:



.....
Ms M E Graham - Trustee

**Independent Examiner's Report to the Trustees of
European Parkinson's Disease Association**

I report to the Trustees on my examination of the financial statements of European Parkinson's Disease Association (the charity) for the year ended 31 December 2019.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act). You are satisfied that your charity is not required by charity law to be audited and have chosen instead to have an independent examination.

I report in respect of my examination of the charity's financial statements carried out under section 44 (1) (c) of the 2005 Act and section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

The charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

1. the accounting records were not kept in accordance with section 130 of the 2011 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Caroline Coleman ACA
A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Date: 28/07/2020

European Parkinson's Disease Association

Statement of Financial Activities
(Incorporating an Income and Expenditure Account)
for the Year Ended 31st December 2019

	Notes	Unrestricted fund £	Restricted funds £	2019 Total funds £	2018 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations	4	26,628	(2)	26,626	22,198
Charitable activities	5				
Member organisation and board meetings		22,374	-	22,374	14,406
Other income		1,895	-	1,895	1,035
Investments		313	-	313	41
Publications		6,774	-	6,774	4,580
Project Income		39,316	13,241	52,557	132,995
Core Income		174,249	81,415	255,664	260,492
Total		271,549	94,654	366,203	435,747
EXPENDITURE ON					
Charitable activities	6				
Member organisation and board meetings		40,223	-	40,223	56,146
Advocacy communication and project development		72,356	-	72,356	221,225
Grant Funded projects		-	100,025	100,025	155,045
Support costs		122,120	2,218	124,338	49,663
Governance costs		5,760	-	5,760	7,656
Total		240,459	102,243	342,702	489,735
Foreign exchange gains/losses		(2,285)	-	(2,285)	(5,852)
NET INCOME/(EXPENDITURE)		28,805	(7,589)	21,216	(59,840)
RECONCILIATION OF FUNDS					
Total funds brought forward		95,309	186,154	281,463	341,303
TOTAL FUNDS CARRIED FORWARD		<u>124,114</u>	<u>178,565</u>	<u>302,679</u>	<u>281,463</u>

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Financial Position

31st December 2019

	Notes	2019 £	2018 £
CURRENT ASSETS			
Debtors	11	68,704	89,640
Cash at bank and in hand		<u>411,317</u>	<u>385,237</u>
		480,021	474,877
CREDITORS			
Amounts falling due within one year	12	(177,342)	(193,414)
		<u>302,679</u>	<u>281,463</u>
NET CURRENT ASSETS			
		<u>302,679</u>	<u>281,463</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>302,679</u>	<u>281,463</u>
NET ASSETS		<u>302,679</u>	<u>281,463</u>
FUNDS	14		
Unrestricted funds		124,112	95,309
Restricted funds		<u>178,567</u>	<u>186,154</u>
TOTAL FUNDS		<u>302,679</u>	<u>281,463</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2019.


The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2019 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by:



.....
Mr K Onarheim - Trustee



.....
Ms S Lindvall - Trustee

The notes form part of these financial statements

European Parkinson's Disease Association**Statement of Cash Flows**
for the Year Ended 31st December 2019

	Notes	2019 £	2018 £
Cash flows from operating activities			
Cash generated from operations	1	<u>28,365</u>	<u>49,786</u>
Net cash provided by operating activities		<u>28,365</u>	<u>49,786</u>
Cash flows from investing activities			
Foreign exchange gains/losses		<u>(2,285)</u>	<u>(5,852)</u>
Net cash used in investing activities		<u>(2,285)</u>	<u>(5,852)</u>
		<hr/>	<hr/>
Change in cash and cash equivalents in the reporting period		26,080	43,934
Cash and cash equivalents at the beginning of the reporting period		<u>385,237</u>	<u>341,303</u>
Cash and cash equivalents at the end of the reporting period		<u>411,317</u>	<u>385,237</u>

The notes form part of these financial statements

European Parkinson's Disease Association

Notes to the Statement of Cash Flows
for the Year Ended 31st December 2019

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2019 £	2018 £
Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)	21,216	(59,840)
Adjustments for:		
Foreign exchange losses	2,285	5,852
Decrease/(increase) in debtors	20,936	(89,640)
(Decrease)/increase in creditors	<u>(16,072)</u>	<u>193,414</u>
Net cash provided by operations	<u>28,365</u>	<u>49,786</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.19 £	Cash flow £	At 31.12.19 £
Net cash			
Cash at bank and in hand	<u>385,237</u>	<u>26,080</u>	<u>411,317</u>

Notes to the Financial Statements
for the Year Ended 31st December 2019

1. CHARITY INFORMATION

European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

2. ACCOUNTING POLICIES

Accounting convention

The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

2. ACCOUNTING POLICIES - continued

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period).

Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

Irrecoverable vat

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

European Parkinson's Disease Association

**Notes to the Financial Statements - continued
for the Year Ended 31st December 2019**

4. DONATIONS

	2019	2018
	£	£
Members fees	24,408	18,554
Donations	<u>2,218</u>	<u>3,644</u>
	<u>26,626</u>	<u>22,198</u>

5. INCOME FROM CHARITABLE ACTIVITIES

	2019	2018
	£	£
Member organisation meeting	22,374	14,406
Other income	1,895	1,035
Investments	313	41
Publication income	6,774	4,580
Project income	52,557	132,995
Core income	<u>255,664</u>	<u>260,492</u>
	<u>339,577</u>	<u>413,549</u>

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 7) £	Totals £
Member organisation and board meetings	40,223	-	40,223
Advocacy communication and project development	72,356	-	72,356
Grant Funded projects	100,025	-	100,025
Support costs	63,895	60,443	124,338
Governance costs	-	5,760	5,760
	<u>276,499</u>	<u>66,203</u>	<u>342,702</u>

7. SUPPORT COSTS

	Management £	Finance £	Other £	Governance costs £	Totals £
Support costs	14,926	24,019	21,498	-	60,443
Governance costs	-	-	-	5,760	5,760
	<u>14,926</u>	<u>24,019</u>	<u>21,498</u>	<u>5,760</u>	<u>66,203</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2019**

7. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

	Support costs	Governance costs	2019 Total activities	2018 Total activities
	£	£	£	£
Fundraising	14,926	-	14,926	5,351
Wages	8,693	-	8,693	6,644
Bank charges	-	-	-	753
Financial administration	15,326	-	15,326	13,679
General expenditure	13,062	-	13,062	12,649
Administration costs	8,436	-	8,436	10,587
Independent examination costs	-	5,760	5,760	7,656
	<u>60,443</u>	<u>5,760</u>	<u>66,203</u>	<u>57,319</u>

8. TRUSTEES' REMUNERATION AND BENEFITS

Ms M E Graham received fees totalling £16,747 (2018: £32,350) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees.

9. STAFF COSTS

	2019 £	2018 £
Wages and salaries	<u>8,693</u>	<u>6,644</u>
	<u>8,693</u>	<u>6,644</u>

The average monthly number of employees during the year was as follows:

	2019	2018
Administration	<u>2</u>	<u>-</u>

No employees received emoluments in excess of £60,000.

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund	Restricted funds	Total funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations	22,198	-	22,198
Charitable activities			
Member organisation and board meetings	14,406	-	14,406
Other income	1,035	-	1,035
Investments	41	-	41
Publications	4,580	-	4,580
Project Income	-	132,995	132,995
Core Income	260,492	-	260,492
	<u>302,752</u>	<u>132,995</u>	<u>435,747</u>
Total	302,752	132,995	435,747
EXPENDITURE ON			
Charitable activities			
Member organisation and board meetings	56,146	-	56,146
Advocacy communication and project development	221,225	-	221,225
Grant Funded projects	-	155,045	155,045
Support costs	49,663	-	49,663

**Notes to the Financial Statements - continued
for the Year Ended 31st December 2019**

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted fund £	Restricted funds £	Total funds £
Governance costs	7,656	-	7,656
Total	334,690	155,045	489,735
Foreign exchange gains/losses	(5,852)	-	(5,852)
NET INCOME/(EXPENDITURE)	(37,790)	(22,050)	(59,840)
Transfers between funds	8,934	(8,934)	-
Net movement in funds	(28,856)	(30,984)	(59,840)
RECONCILIATION OF FUNDS			
Total funds brought forward	124,165	217,138	341,303
TOTAL FUNDS CARRIED FORWARD	<u>95,309</u>	<u>186,154</u>	<u>281,463</u>

11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2019 £	2018 £
Trade debtors	68,477	88,888
Prepayments	227	752
	<u>68,704</u>	<u>89,640</u>

12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2019 £	2018 £
Trade creditors	43,913	185,378
Social security and other taxes	5,637	2,276
Net wages	5,568	-
Pension	256	-
Accruals and deferred income	<u>121,968</u>	<u>5,760</u>
	<u>177,342</u>	<u>193,414</u>

13. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted fund £	Restricted funds £	2019 Total funds £	2018 Total funds £
Current assets	246,238	233,783	480,021	474,877
Current liabilities	(122,126)	(55,216)	(177,342)	(193,414)
	<u>124,112</u>	<u>178,567</u>	<u>302,679</u>	<u>281,463</u>

European Parkinson's Disease Association

**Notes to the Financial Statements - continued
for the Year Ended 31st December 2019**

14. MOVEMENT IN FUNDS

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
Unrestricted funds			
General fund	95,309	28,803	124,112
Restricted funds			
PDCS	51,115	(20,478)	30,637
Parkinson's Information	1,168	6,319	7,487
Data Collection	12,498	-	12,498
Treat ER	91,752	-	91,752
European Young Onset PD	29,621	10,772	40,393
Parkinson's Life	-	(4,200)	(4,200)
	<u>186,154</u>	<u>(7,587)</u>	<u>178,567</u>
TOTAL FUNDS	<u>281,463</u>	<u>21,216</u>	<u>302,679</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	271,547	(240,459)	(2,285)	28,803
Restricted funds				
PDCS	-	(20,478)	-	(20,478)
Parkinson's Information	8,696	(2,377)	-	6,319
European Young Onset PD	13,103	(2,331)	-	10,772
Advanced therapies	13,103	(13,103)	-	-
AirLiquide Carers Project	2,444	(2,444)	-	-
Parkinson's Life	57,310	(61,510)	-	(4,200)
	<u>94,656</u>	<u>(102,243)</u>	<u>-</u>	<u>(7,587)</u>
TOTAL FUNDS	<u>366,203</u>	<u>(342,702)</u>	<u>(2,285)</u>	<u>21,216</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued for the Year Ended 31st December 2019

14. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.18 £	Net movement in funds £	Transfers between funds £	At 31.12.18 £
Unrestricted funds				
General fund	124,165	(37,790)	8,934	95,309
Restricted funds				
PDCS	107,813	(56,698)	-	51,115
Research/Clinical trials	6,853	116	(6,969)	-
Parkinson's Information	2,823	(1,655)	-	1,168
Global Campaign	3,951	(1,516)	(2,435)	-
Data Collection	15,353	(2,855)	-	12,498
Treat ER	80,345	10,937	470	91,752
European Young Onset PD	-	29,621	-	29,621
	<u>217,138</u>	<u>(22,050)</u>	<u>(8,934)</u>	<u>186,154</u>
TOTAL FUNDS	<u>341,303</u>	<u>(59,840)</u>	<u>-</u>	<u>281,463</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	302,752	(334,690)	(5,852)	(37,790)
Restricted funds				
PDCS	39,000	(95,698)	-	(56,698)
Research/Clinical trials	450	(334)	-	116
Parkinson's Information	9,244	(10,899)	-	(1,655)
Global Campaign	29,450	(30,966)	-	(1,516)
Data Collection	-	(2,855)	-	(2,855)
Treat ER	12,636	(1,699)	-	10,937
European Young Onset PD	<u>42,215</u>	<u>(12,594)</u>	<u>-</u>	<u>29,621</u>
	<u>132,995</u>	<u>(155,045)</u>	<u>-</u>	<u>(22,050)</u>
TOTAL FUNDS	435,747	(489,735)	(5,852)	(59,840)

The restricted fund project - PDCS, has been independently funded by the following donees:

	2019 £	2018 £
Abbvie Biopharmaceuticals Sarl	-	8,752
Boston Scientific International SA	-	4,584
UCB Biopharma SPRL	-	8,764
Acorda Therapeutics	-	16,026
Others	-	875

15. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st December 2019.

European Parkinson's Disease Association**Detailed Statement of Financial Activities**
for the Year Ended 31st December 2019

	2019 £	2018 £
INCOME AND ENDOWMENTS		
Donations		
Members fees	24,408	18,554
Donations	<u>2,218</u>	<u>3,644</u>
	26,626	22,198
Charitable activities		
Member organisation meeting	22,374	14,406
Publication income	6,774	4,580
Investments	313	41
Other income	1,895	1,035
Core income	255,664	260,492
Project income	<u>52,557</u>	<u>132,995</u>
	<u>339,577</u>	<u>413,549</u>
Total incoming resources	366,203	435,747
EXPENDITURE		
Charitable activities		
Members meeting	38,052	25,657
Administration Board	31,991	24,390
PDG think tank	2,171	6,099
Website	7,922	15,660
Parkinson's life	58,392	58,241
Exhibitions	12,999	1,795
Communications	10,050	8,430
Social media	20,470	9,244
Digital strategy	10,228	17,702
Member organisation outreach	11,934	6,885
GDPR	1,076	8,733
PDCS	28,089	95,699
Research/clinical trials	1,550	334
Parkinson's info	2,748	10,899
Data collection	1,812	2,855
Global campaign	2,404	30,966
Treat ER	250	1,698
EYOPD	2,380	12,594
Political affairs and policy	1,877	94,535
AirLiquide carers project	28,557	-
Adviser	<u>1,547</u>	<u>-</u>
	276,499	432,416
Support costs		
Management		
Fundraising	14,926	5,351
Finance		
Wages	8,693	6,644
Bank charges	-	753
Carried forward	8,693	7,397

This page does not form part of the statutory financial statements

European Parkinson's Disease Association**Detailed Statement of Financial Activities**
for the Year Ended 31st December 2019

	2019 £	2018 £
Finance		
Brought forward	8,693	7,397
Financial administration	<u>15,326</u>	<u>13,679</u>
	24,019	21,076
Other		
General expenditure	13,062	12,649
Administration costs	<u>8,436</u>	<u>10,587</u>
	21,498	23,236
Governance costs		
Independent examination costs	<u>5,760</u>	<u>7,656</u>
Total resources expended	<u>342,702</u>	<u>489,735</u>
Net income/(expenditure) before gains and losses	23,501	(53,988)
Realised recognised gains and losses		
Foreign exchange gains/losses	<u>(2,285)</u>	<u>(5,852)</u>
Net income/(expenditure)	<u>21,216</u>	<u>(59,840)</u>

European Parkinson's Disease Association

Statement of Income and Expenditure for the Year Ended 31st December 2019

	2019 (£)	2019 (€)	2018 (£)	2018 (€)
INCOME AND ENDOWMENTS				
Donations				
Members Fees	24,408	28,844	18,554	20,667
Donations	<u>2,218</u>	<u>2,621</u>	<u>3,644</u>	<u>4,059</u>
	26,626	31,465	22,198	24,726
Charitable Activities				
Member organisation meeting	22,374	26,440	14,406	16,047
Publication Income	6,774	8,005	4,580	5,102
Investments	313	370	41	46
Other income	1,895	2,239	1,035	1,153
Core income	255,664	302,131	260,492	290,161
Project income	<u>52,557</u>	<u>62,109</u>	<u>132,995</u>	<u>148,143</u>
	<u>339,577</u>	<u>401,294</u>	<u>413,549</u>	<u>460,652</u>
Total incoming resources	366,203	432,759	435,747	485,378
EXPENDITURE				
Charitable activities				
Members meeting	38,052	44,968	25,657	28,579
Administration Board	31,991	37,805	24,390	27,168
PDG think tank	2,171	2,566	6,099	6,794
Website	7,922	9,362	15,660	17,444
Parkinson's life	58,392	69,005	58,241	64,874
Exhibitions	12,999	15,362	1,795	1,999
Communications	10,050	11,877	8,430	9,390
Social Media	20,470	24,190	9,244	10,297
Digital strategy	10,228	12,087	17,702	19,718
Member organisation outreach	11,934	14,103	6,885	7,669
GDPR	1,076	1,272	8,733	9,728
PDCS	28,089	33,194	95,699	106,599
Research/clinical trials	1,550	1,832	334	372
Parkinson's info	2,748	3,247	10,899	12,140
Data collection	1,812	2,141	2,855	3,180
Global campaign	2,404	2,841	30,966	34,493
Treat ER	250	295	1,698	1,891
EYOPD	2,380	2,813	12,594	14,028
Political affairs and policy	1,877	2,218	94,535	105,302
AirLiquide carers project	28,557	33,747	-	-
Adviser	<u>1,547</u>	<u>1,828</u>	-	-
	276,499	326,753	432,416	481,665
Support costs				
Management				
Fundraising	14,926	17,639	5,351	5,960
Finance				
Wages	8,693	10,273	6,644	7,401
Carried forward	8,693	10,273	6,644	7,401
Finance				
Brought forward	8,693	10,273	6,644	7,401
Bank charges	-	-	753	839

This page does not form part of the statutory financial statements

Financial administration	<u>15,326</u>	<u>18,112</u>	<u>13,679</u>	<u>15,237</u>
	24,019	28,385	21,076	23,477
Other				
General expenditure	13,062	15,436	12,649	14,090
Administration costs	<u>8,436</u>	<u>9,969</u>	<u>10,587</u>	<u>11,793</u>
	21,498	25,405	23,236	25,883
Governance costs				
Independent examination costs	<u>5,760</u>	6,807	<u>7,656</u>	8,528
Total resources expended	<u>342,702</u>	<u>404,988</u>	<u>489,735</u>	<u>545,514</u>
Net income/(expenditure) before gains and losses	23,501	27,772	(53,988)	(60,137)
Realised recognised gains and losses				
Foreign exchange gains/losses	<u>(2,285)</u>	<u>(2,700)</u>	<u>(5,852)</u>	<u>(6,519)</u>
Net income/expenditure	<u>21,216</u>	<u>25,072</u>	<u>(59,840)</u>	<u>(66,656)</u>

European Parkinson's Disease Association
Statement of Financial Position for the Year Ended 31st December 2019

	2019 (£)	2019 (€)	2018 (£)	2018 (€)
CURRENT ASSETS				
Debtors	68,704	81,191	89,640	99,850
Cash at bank and in hand	<u>411,317</u>	<u>486,074</u>	<u>385,237</u>	<u>429,114</u>
	480,021	567,265	474,877	528,964
CREDITORS				
Amounts falling due within one year	(177,342)	(209,574)	(193,414)	(215,443)
NET CURRENT ASSETS	<u>302,679</u>	<u>357,691</u>	<u>281,463</u>	<u>313,520</u>
TOTAL ASSETS LESS CURRENT LIABILITIES	302,679	357,691	281,463	313,520
NET ASSETS				
FUNDS				
Unrestricted funds	124,112	146,669	95,309	106,164
Restricted funds	<u>178,567</u>	<u>211,022</u>	<u>186,154</u>	<u>207,356</u>
TOTAL FUNDS	<u>302,679</u>	<u>357,691</u>	<u>281,463</u>	<u>313,520</u>